Background There is a growing armamentarium for the treatment of moderate-to-severe
ulcerative colitis. We aimed to compare the relative efficacy and safety of biologics and small …

Immune cell trafficking is a critical element of the intestinal immune response, both in
homeostasis and in pathological conditions associated with inflammatory bowel disease …

Orally targeted strategy of anti-inflammatory agents has attracted tremendous attention for
reducing highly health-care costs and enhancing the intervention efficiency of ulcerative …

Inflammatory bowel disease (IBD) is a chronic immune-mediated inflammation of the
gastrointestinal tract with a highly heterogeneous presentation. It has a relapsing and …

Importance Olamkicept, a soluble gp130-Fc-fusion-protein, selectively inhibits interleukin 6
(IL-6) trans-signaling by binding the soluble IL-6 receptor/IL-6 complex. It has anti …

Many patients with inflammatory bowel disease (IBD) have persistent symptoms and
disease activity despite the best available medical or surgical treatments. These patients are …

Gastroenterologists will be all too familiar with the difficult decisions that managing
inflammatory bowel disease often presents. How aggressively should I treat this patient? Do …

Inflammatory bowel disease (IBD), historically subdivided into Crohn's disease and
ulcerative colitis, is a very heterogeneous condition. While the tendency in medicine is to try …

Ulcerative colitis (UC) is a chronic inflammatory illness affecting the colon and rectum, with
current treatment methods being unable to meet the clinical needs of ulcerative colitis …

Despite huge advances in understanding the molecular basis of IBD, clinical management
has continued to rely on a “trial and error” approach. In addition, a therapeutic ceiling has …